Saturday July 04 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
  • A-Z

BioJournal - Datamonitor

http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor.html

Stakeholder Opinions Head and Neck Cancer
Stakeholder Opinions Head and Neck Cancer
Key issues in head and neck cancer including disease overview and epidemiology, current treatment patterns and controversies, unmet needs and key stakeholder opinions. The clinical pipeline and profiles of the late-phase products are also included.
Commercial and Pipeline Insight - Systemic antifungals
Commercial and Pipeline Insight - Systemic antifungals
The systemic antifungals market accounts for $3.1bn of the total $41bn anti-infectives market. A wave of new products coinciding with patent expiry of two widely used compounds will shake up the market for systemic infections, further polarizing between winners and losers. Key changes are forcing a rethink of management strategies and clinical trial design.
Pipeline Insight - Orphan Diseases in CNS - Part I Huntington's Disease
Pipeline Insight - Orphan Diseases in CNS - Part I Huntington's Disease
The current Huntington’s disease market is comprised of off-label prescriptions of psychotropic drugs. In the near term, two pipeline drugs are set to enter the market, demonstrating the viability of this disease as a primary marketing indication. In the longer term, with a strong genetic link and reliable diagnostic test, prophylactic treatment with a disease modifying drug could prove lucrative.
Licensing Strategies - Examining Today’s Pharmaceutical Licensing Trends
Licensing Strategies - Examining Today’s Pharmaceutical Licensing Trends
With Pharma struggling to maintain its pipelines and portfolios with products developed in-house, companies are increasingly turning to licensing. However, the search for late-stage developmental products is becoming tougher and more expensive, and companies are now looking towards licensing earlier-stage compounds.
Pipeline Insight - Substance Dependence - Part I - Nicotine
Pipeline Insight - Substance Dependence - Part I - Nicotine
The high prevalence of nicotine dependence, strong uptake of Pfizer’s Chantix (varenicline), and the launch of new innovative therapies will cause the nicotine dependence prescription drug market to grow to $4.6 billion across the seven major markets by 2016. Innovative therapies are set to offer patients a convenient dosing regimen and thereby carrying the potential for improved compliance.
Commercial and Pipeline Insight - Hepatitis B
Commercial and Pipeline Insight - Hepatitis B
Fuelled by an increasing disease awareness, the growing use of new, expensive drugs as well as combination therapy, the HBV drugs market, sized at $431m in 2006 across the seven major markets, will nearly triple in size by 2016. Rapid growth until 2011 will slow down in the following years as a result of genericization and the beginning impact of routine HBV vaccination.
Cardiovascular market overview - Raft of patent expires threaten blockbusters
Cardiovascular market overview - Raft of patent expires threaten blockbusters
Datamonitor expects the cardiovascular market to remain stable with sales only showing negligible growth between 2006 and 2016, below the 3% growth predicted for the SU sold. Generic products will become increasingly important as the majority of products will have lost IP protection, accounting for 30% of cardiovascular sales and 65% of SU sold in 2016.
Molecular Targeted Cancer Therapies  Can anything else revolutionize the market
Molecular Targeted Cancer Therapies Can anything else revolutionize the market
Approaches to cancer treatment continue to incorporate molecular targeted therapies into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge.
Analysis of the Pharmaceutical Market to 2012 - Segmented by Drug Target Family
Analysis of the Pharmaceutical Market to 2012 - Segmented by Drug Target Family
Drug targets are the critical link between drugs and their role in the treatment of medical disorders. By grouping drug targets into key protein families, this report provides a comprehensive analysis of the prescription pharmaceutical market by not just molecule type and therapy area, but also by target family.
Acute Stroke - TPA spurs infrastructure changes for the better
Acute Stroke - TPA spurs infrastructure changes for the better
Stroke is one of the top three leading causes of death worldwide and an area of high unmet needs. TPA is limited to a low number of ischemic stroke patients due to a short therapeutic time window, but it is still the best therapy available. TPA is responsible for major changes and advances in the way stroke patients are cared for, which is expected to evolve further.
Renal Cancer - Targeted therapies rapidly take hold of market
Renal Cancer - Targeted therapies rapidly take hold of market
In the 7 major markets, Datamonitor estimates that the incidence of RCC in 2007 will total 86,800 cases. Around 25% of all RCC patients are diagnosed with Stage IV disease; the 2-year survival rate for these patients is around 23%. This low survival rate and the fact that a significant proportion of Stage IIII patients relapse with Stage IV disease mean there is significant unmet need in RCC.
Antithrombotics - Market expands as disease management focuses on prevention
Antithrombotics - Market expands as disease management focuses on prevention
Datamonitor expects the antithrombotics market to peak at just over $20 billion in 2012, across the seven major markets. The growth will be driven by the uptake of the novel oral anticoagulants - Bayer's Xarelto and BI's Rendix - which are expected to launch simultaneously, in 2008.
Infertility - Optimizing a market bounded by social opinion and physician preference
Infertility - Optimizing a market bounded by social opinion and physician preference
The market for infertility drugs is a complex and dynamic arena shaped by numerous factors such as changing social attitudes, national legislation, and prescriber preferences. Brand strength and diverse portfolios have allowed Organon, Merck Serono and Ferring to secure a firm foothold in the market, worth over $1 billion in 2006, and represent tough competition.
Commercial and Pipeline Insight Allergic Rhinitis
Commercial and Pipeline Insight Allergic Rhinitis
The allergic rhinitis market will continue to decline over the next few years, after which it will resume limited growth due to the introduction of new compounds and combination products. These will drive the expansion of sales in existing classes as they exhibit safety and convenience advantages. Meanwhile, immunotherapy is expected to move from its niche position into mainstream therapy.
Upper GI Disorders - Innovation needed to overcome generic threat
Upper GI Disorders - Innovation needed to overcome generic threat
The upper GI market, defined as gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD) and dyspepsia indications, achieved sales of just over $19 billion in 2006, with minimal growth since 2005. All major PPI brands will lose patent protection in the next 10 years, resulting in a major increase in generics and a declining market value.
HIV Therapy Dynamics
HIV Therapy Dynamics
Despite several developments in efforts to tackle the spread of HIV, the total number of people living with HIV has continued to increase across the 6MM. However, significant advances in HIV disease understanding, treatment and management mean that the outlook for patients has considerably improved.
Orthopedics: Global Industry Guide
Orthopedics: Global Industry Guide
Datamonitor's Orthopedics: Global Industry Guide is an essential resource for top-level data and analysis covering the orthopedics industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Biotechnology: Global Industry Guide
Biotechnology: Global Industry Guide
Datamonitor's Biotechnology: Global Industry Guide is an essential resource for top-level data and analysis covering the biotechnology industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis
Generics: Global Industry Guide
Generics: Global Industry Guide
Datamonitor's Generics: Global Industry Guide is an essential resource for top-level data and analysis covering the generics industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Biosimilars Series Strategic issues - Potential remains uncertain
Biosimilars Series Strategic issues - Potential remains uncertain
Significant barriers to entry into the biosimilars market exist. High up-front investment and the need for specific expertise favor big players. Understanding of the marketplace is critical for success acceptance by key stakeholders is crucial for market uptake of biosimilars and achieving preferential reimbursement status through constant review of the pricing strategy is desirable.

 

Cancer Overview - Increasing diversity offers both high risk and reward
Cancer Overview - Increasing diversity offers both high risk and reward
In 2007, more than 3 million new cases of solid tumors are forecast to be diagnosed across the seven major pharmaceutical markets, obviously representing an enormous market potential. Lower incidence tumor types are becoming increasingly attractive to drug developers, due to high levels of unmet need which can result in significant financial rewards.
Parkinson's Disease - Market to grow as first round of lifecycle management strategies succeed
Parkinson's Disease - Market to grow as first round of lifecycle management strategies succeed
The PD market is set to continue to grow over the next 7 years, reaching over $2.37 billion in 2013, a 39% increase from 2006 levels. Combinations, reformulations, and indication expansions will drive the majority of this growth, with key brands expected to be Novartis/Orion's Stalevo, GlaxoSmithKline's (GSK's) Requip Modutab, and UCB-Schwarz's Neupro.
Pricing and Reimbursement Series NICE  its impact on the UK healthcare system and beyond
Pricing and Reimbursement Series NICE its impact on the UK healthcare system and beyond
NICE is one of the most advanced cost effectiveness assessment bodies operating in the major pharmaceutical markets. Since it was established it has had an increasing impact on the availability of new drugs in England and Wales, but has also generated considerable attention globally
Neuropathic Pain - Emerging drugs fail to capitalize in lucrative market
Neuropathic Pain - Emerging drugs fail to capitalize in lucrative market
The neuropathic pain market is forecast to double from 2006 to reach over $7 billion by 2016. At this time, the current late-stage neuropathic pain pipeline is forecast to take only 18% of the total market share, highlighting an opportunity for better pipeline drugs that demonstrate improved pain management. The most promising and closest pipeline drug to market is UCB's Vimpat (lacosamide).
Migraine - Opportunities will exist in the wake of generic attack
Migraine - Opportunities will exist in the wake of generic attack
With the seven triptan brands continuing to dominate acute migraine treatment and Ortho-McNeil's Topamax (topiramate) driving sales in the prophylactic market, 7MM revenues of anti-migraine drugs increased by 8.1% from 2005 to $3.7 billion in 2006. The US accounted for 80% of the 7MM total in 2006, Whilst in the 5EU, France is the largest market for migraine-specific drug sales.
Monoclonal Antibodies Report Part II: Companies - Holding mAbs in portfolio promises protection against the looming 2011-12 patent cliff
Monoclonal Antibodies Report Part II: Companies - Holding mAbs in portfolio promises protection against the looming 2011-12 patent cliff
"IntroductionThis report provides a comprehensive strategic analysis of the mAb market out to 2012 by company. It identifies four 'established' and four 'emerging' players within the mAb sector which are forecast to play the most commercially significant role within this market.
Osteoporosis Intermittent dosing drives market growth
Osteoporosis Intermittent dosing drives market growth
The long-standing unmet need of the osteoporosis market has been for improved adherence to treatment. Two pipeline products, Amgen's Denosumab and Novartis' Aclasta (zoledronate), have answered this demand with intermittent dosing schedules and consequently are expected to generate blockbuster revenues. This will rejuvenate the market which is otherwise stalling under multiple patent expiries.
Biosimilars Series Regulatory and development issues hurdles exist but are surmountable
Biosimilars Series Regulatory and development issues hurdles exist but are surmountable
Europe serves as a model for other countries looking to define their own regulatory approval criteria. The US is on the brink of passing legislation to establish a statutory pathway for biosimilars approval but the opposing interests of biosimilar and innovative companies may result in further delays. Development of biosimilars presents many challenges and potential pitfalls.
Hospital Antibacterials A market beyond MRSA
Hospital Antibacterials A market beyond MRSA
The Hospital antibacterials market accounted for $9.9bn of the total $41bn anti-infectives market. Increasingly resistant and problematic pathogens make this an attractive target for premium priced products outside of the largely genericized Community market. However, high concentrations of patent expiries and similarly targeted product launches imply a highly competitive commercial landscape.
Business Blogging for Pharma
Business Blogging for Pharma
Social media are shifting the way that the global economy operates. Internet journals and communities have enabled consumers to communicate their experiences with companies' products and services to other consumers. A consequence of consumer-generated marketing is that relationship management throughout the lifecycle of a product is taking the place of mass marketing in consumer-driven industries.
Antidiabetics Safety becomes the critical factor for success
Antidiabetics Safety becomes the critical factor for success
The diabetes epidemic has contributed in the growth of the antidiabetics market the past few years. Since the prevalence of diabetes continues to increase, the market will further expand. While early therapy is dominated by generically available agents, and the later stages by insulin, the number of unmet needs in the diabetes treatment, warrants that novel agents will have a place in the market.
Launch Strategies Analyzing Market Trends and Regulatory Impacts
Launch Strategies Analyzing Market Trends and Regulatory Impacts
With fewer truly novel products entering the market, combined with increasing developmental time and spend, and declining ROI, successful launches have never been more important for pharmaceutical companies. Therefore, to ensure a successful launch, manufacturers must employ a multitude of timely strategies to ensure their product enter the market as soon and as smoothly as possible.
Heart failure Weak pipeline dominated by new indications and add-on diuretics
Heart failure Weak pipeline dominated by new indications and add-on diuretics
Datamonitor expects few new products to emerge from a week pipeline for both acute and chronic heart failure. Sales in the seven major markets will be modest with all the new drugs being add-on therapies to current standard regimes. Significant unmet patients needs will remain in both acute and chronic heart failure.
R&D Strategies Incremental improvements and paradigm shifts in strategy are both necessary to boost productivity
R&D Strategies Incremental improvements and paradigm shifts in strategy are both necessary to boost productivity
Waves of technological advancements have powered significant evolution in R&D from serendipitous drug discovery, through to rational drug design. However, as the low-hanging fruit has been picked, and recent technological advances have failed to yield high numbers of new therapies, the search is on to identify R&D strategies to improve R&D productivity
Female Sexual Dysfunction Prescription Drug Pipeline Overview 2007
Female Sexual Dysfunction Prescription Drug Pipeline Overview 2007
Female sexual dysfunction (FSD) affects an estimate 84 million women across the seven major pharmaceutical markets and represents a significant opportunity for investment. Despite its high prevalence, FSD is poorly understood and defined. Currently there is just one product approved for the treatment of FSD; P&G's Intrinsa (testosterone) is marketed in Germany, France and the UK.
Pediatric and Adolescent Vaccines
Pediatric and Adolescent Vaccines
The pediatric and adolescent vaccines market encompasses many different classes. DTP and MMR combinations continue to form the mainstay of childhood immunization; however, their growth potential is limited. The key opportunities lie in novel, innovative additions to established schedules, particularly pneumococcal (Prevnar), conjugated meningococcal (Menactra) and HPV (Gardasil) vaccines.
Patient Empowerment empowered patients can change healthcare outcomes and impact the pharmaceutical industry
Patient Empowerment empowered patients can change healthcare outcomes and impact the pharmaceutical industry
Datamonitor has identified the key trends and events that drive patient empowerment and impact the pharmaceutical industry. These range from the increased access to information via internet and the rising pressures of cost containment through to how patient empowerment is affecting access to drugs as well as changing pharmaceutical marketing strategies and their public image.
Antihypertensives New class opportunity offset by key patent expiries
Antihypertensives New class opportunity offset by key patent expiries
Datamonitor expects the antihypertensives market to reach almost $40 billion, across the seven major markets, by 2016. The growth will be driven by the uptake of Novartis's Tekturna, as well as increased use of ARBs, and their combinations. However, the expiries of some key patents, particularly Pfizer's Norvasc and Merck's Cozaar, will restrain market growth.
Antidyslipidemics The competitive cost-conscious antidyslipidemics market presents challenges
Antidyslipidemics The competitive cost-conscious antidyslipidemics market presents challenges
The restrictive, highly competitive antidyslipidemic market is going to become even further genericized, which will add to the challenges that drug makers are facing. Despite over 300m people being eligible for antidyslipidemic treatment, there is still a lot of under-diagnosis and under-treatment, but it will be a major issue capturing all the eligible population.
Asthma and COPD Combination products still have blockbuster potential
Asthma and COPD Combination products still have blockbuster potential
Detailed analysis of the Asthma and COPD market. 10 year sales forecast for all major drugs brands in these indications, taking into account new treatment trends, clinical trial data, patent expirations and key new product launches in the 7 major markets.
HIV Reshaping Treatment Paradigms
HIV Reshaping Treatment Paradigms
Detailed analysis of the antiretroviral therapy market. 10 year sales forecast for marketed drugs and key pipeline compounds, factoring in clinical trial results, new product launches and patent expiries.

 

Scope of this report

 

 

* In-depth analysis of the current HIV market across the major US and EU markets

 

* Thorough assessment of underlying commercial and clinical factors shaping the antiretroviral market

 

* Detailed sales forecasts for the three major antiretroviral classes, molecules and brands in each of the six major markets

 

* Case study analysis of the entry inhibitor class focusing on the competitive environment and critical success factors
Upper GI Disorders Generics will limit pipeline profit
Upper GI Disorders Generics will limit pipeline profit
Gastroesophageal reflux disease (GERD), functional dyspepsia (FD) and peptic ulcer disease (PUD) represent a group of common gastrointestinal (GI) conditions, which can be referred to collectively as upper GI disorders. Gastric acid suppression remains the cornerstone of therapy in upper GI disorders, with particular focus on reducing symptoms and eradicating H. pylori, if present.
Top 20 Cancer Therapy Brands Sales of targeted therapies overtake cytotoxics in 2006
Top 20 Cancer Therapy Brands Sales of targeted therapies overtake cytotoxics in 2006
Sales of the Top 20 cancer therapy brands in each of the seven major markets totaled $24.5 billion in 2006 and are forecast to grow at a CAGR of 6.6% to $45.9 billion by 2016. Four newly marketed drugs are expected to become part of the Top 20 cancer therapy brands during the forecast period and are set to increase the 2016 sales of the existing Top 20 cancer therapy brands to $52.7 billion.
Disease Management and Drug Adherence Strategies to support patients and enhance treatment persistence
Disease Management and Drug Adherence Strategies to support patients and enhance treatment persistence
Failure to take medication as prescribed significantly increases the risk that patients will experience complications resulting in injury or death, and propagate higher healthcare costs overall. The medical establishment's approach to adherence is changing as it becomes clear that the responsibility of achieving adherence is not solely the patient's, but rather is shared among stakeholders.
Primary Brain Cancer
Primary Brain Cancer
Incidence of primary brain cancer across the seven major markets in 2007 is estimated to be 47,000. Over half of these cases will be glioblastoma multiforme, for which survival prospects are dismal. The median survival for this group of patients is 1.2 years and only 27% of patients are alive after two years. The level of unmet need is therefore high in this disease.
Depression Atypical lifecycle management strategy rejuvenates depression market
Depression Atypical lifecycle management strategy rejuvenates depression market
Novel pipeline drugs, lifecycle management of the current branded antidepressants, and development of atypical antipsychotics for depression are set to grow the depression market through to 2010 when it will peak at $14.6 billion. Thereafter, however, generic incursion of the atypical antipsychotics and the remaining branded antidepressants will see the depression market value drop to 2016.
Insomnia Strong brand identity critical to differentiation in an increasingly crowded market
Insomnia Strong brand identity critical to differentiation in an increasingly crowded market
Ambien has remained the clear leader in the insomnia market for over a decade, with 2006 sales of over $2.3 billion across the seven major markets. The success of Ambien is attributable to a favorable side-effect profile and half-life. However, due to recent patent expiries in the US and Japan, Ambien's leadership status is finally under threat and the market is undergoing some dramatic changes.
Multiple Sclerosis Continued growth makes the MS market a highly attractive investment
Multiple Sclerosis Continued growth makes the MS market a highly attractive investment
The dynamic MS market continues to grow unabated; seven major market revenues increased 14.7% from 2005 to $4.6 billion in 2006. Growth is driven by the highly successful beta-interferon brands, Teva's Copaxone (glatiramer acetate), and the recent relaunch of Tysabri; the first launch of a new MS treatment for six years.
Osteoporosis Risk management and reformulation offer best defense against generic onslaught
Osteoporosis Risk management and reformulation offer best defense against generic onslaught
The osteoporosis market is due a major upheaval when market leader Fosamax (alendronate) loses its US patent. The resultant heightened competition will force market players to implement radical lifecycle management strategies to safeguard their franchise revenue. New market entrants provide further complexity to the competitive landscape but will also drive market growth over the next ten years.
Monoclonal Antibodies Report Part I
Monoclonal Antibodies Report Part I
The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2012 and assessing trends by product, company, therapy area, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.
Spending on Telehealth Solutions in Europe 2007 to 2012 (Databook)
Spending on Telehealth Solutions in Europe 2007 to 2012 (Databook)
The telehealth market will continue to grow as the population, particularly the elderly and chronically ill, and technology adoption increase.
Spending on Telehealth Solutions in North America through 2007 to 2012 (Databook)
Spending on Telehealth Solutions in North America through 2007 to 2012 (Databook)
The telehealth market will continue to grow as the population, particularly the elderly and chronically ill, and technology adoption increase.
Irritable Bowel Syndrome Potentially profitable market is open for the taking
Irritable Bowel Syndrome Potentially profitable market is open for the taking
Irritable bowel syndrome (IBS) is a common disease affecting 1020% of the total adult population, particularly women, in which recurrent abdominal pain or discomfort is associated with defecation or changes in bowel habit. The majority of sufferers have never consulted a physician about their symptoms and remain undiagnosed.
Supportive Care in Oncology Significant growth opportunities exist in new supportive care indications
Supportive Care in Oncology Significant growth opportunities exist in new supportive care indications
Supportive care can be defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies, in particular cytotoxic chemotherapy. While the antihormonal therapies and novel molecular targeted therapies do not exist without some toxicity, these are not as severe as those associated with chemotherapy.
Hepatocellular Carcinoma Opportune indication for novel therapies
Hepatocellular Carcinoma Opportune indication for novel therapies
The close association with hepatitis means that hepatocellular carcinoma (HCC) is common in developing countries where hepatitis B and C infections are endemic. However, the increasing prevalence of hepatitis in the West means that incidence of HCC in the US and Europe is expected to increase significantly over the coming years.
Generic Series An Introduction to the Canadian Generics Market Key trends and leading companies shaping the market
Generic Series An Introduction to the Canadian Generics Market Key trends and leading companies shaping the market
The Canadian pharmaceutical market is the 8th largest globally and as such represents an important market for generics manufacturers. Although historically dominated by domestic generics companies, mergers and acquisitions over the last five years have increased the dominance of foreign players.
Female Sexual Dysfunction Results from Datamonitor's 2005 physician survey
Female Sexual Dysfunction Results from Datamonitor's 2005 physician survey
Patients in a clinical population receive drug and non-drug therapy for female sexual dysfunction, yet a third remain refractory to treatment, highlighting a need for a formally approved product for FSD. There is a low level of satisfaction with the classification guidelines, further limiting diagnosis, already hampered by embarrassment, lack of physician awareness and an unclear referral system.
Fibromyalgia Potentially lucrative market soon to become reality
Fibromyalgia Potentially lucrative market soon to become reality
Mainly affecting women, fibromyalgia syndrome affects six million people in the US alone. This relatively common yet poorly understood syndrome is characterized by widespread muscle pain and fatigue and remains substantially underserved by the medical profession and the pharmaceutical industry. Currently, there are no drugs licensed to treat fibromyalgia in the US, Japan or Europe.
Disease Modification in Rheumatoid Arthritis Competition for the anti-TNF failure patient population increases
Disease Modification in Rheumatoid Arthritis Competition for the anti-TNF failure patient population increases
The treatment of Rheumatoid Arthritis (RA) has been rapidly evolving over the last decade. The success of the next wave of novel RA therapies depends on their ability to address the key issue of cost effectiveness, as the patient population for anti-TNF's is reaching a maximum and competition moves to anti-TNF failure patients.
Insomnia Targeting the sleep maintenance market
Insomnia Targeting the sleep maintenance market
The launch of serotonin antagonists which are largely aimed at treating sleep maintenance is set to make a substantial impact on the insomnia market, which will increase in value across the seven major markets from $6.1 billion in 2006 to $7.7 billion in 2016.
Benchmarking Patent Expiries Key Factors Affecting Brand Erosion at Patent Expiry
Benchmarking Patent Expiries Key Factors Affecting Brand Erosion at Patent Expiry
With declining returns from drug development pipelines, preservation of branded revenues is key for manufacturers. Inevitably though, once the core product patent of a pharmaceutical drug expires, generic companies will launch their own, cheaper versions of the drug, encouraging product switching and eroding the revenues of branded pharmaceuticals.
Antithrombotics Reaching the untreated prophylaxis market
Antithrombotics Reaching the untreated prophylaxis market
Novel oral anticoagulants and antiplatelet agents will have a profound impact on the antithrombotics market. Datamonitor expects Bayer's rivaroxaban and Sankyo/Eli Lilly's prasugrel to achieve blockbuster status. Parenteral anticoagulants are not expected to be large revenue generators, due to low clinical unmet need in this market segment and strong competition from current gold standard agents.
Dyslipidemia - Pipeline agents unlikely to rejuvenate the market
Dyslipidemia - Pipeline agents unlikely to rejuvenate the market
At present, despite the availability of numerous agents for the treatment of dyslipidemia, there is significant scope for expanding the market by improving diagnosis and treatment of dyslipidemia patients. However, for new agents, gaining a secure foothold on the market will be challenging, but their chances can be improved through targeting niche patient populations and conducting outcome trials.
Influenza Vaccines - Pandemic threat revitalizes the sector
Influenza Vaccines - Pandemic threat revitalizes the sector
The influenza vaccine market, sized at approximately $2.2 billion in 2006, yields many challenges. Demand is highly variable, and only large players are able to cope with the need for annual updates and the costly manufacturing process. However, driven by the increasing pandemic threat, the market is growing fast and is predicted to more than double in size by 2016.
Hematological Malignancies Pursuit for the next blockbuster intensifies
Hematological Malignancies Pursuit for the next blockbuster intensifies
Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity. Pipeline candidates classified as molecular targeted therapies, cytotoxic therapies and immunotherapeutic agents, may offer attractive therapeutic additions and Datamonitor's insight into their clinical and commercial potential is provided.
Multiple Sclerosis The oral revolution
Multiple Sclerosis The oral revolution
The launch of five novel orally administered disease-modifiers is set to revolutionize the multiple sclerosis (MS) market, which will more than double in value across the seven major markets from 2006 to reach $10.7 billion in 2016.
Pricing and Reimbursement Series Medicare Part D's progress so far
Pricing and Reimbursement Series Medicare Part D's progress so far
The roll-out of Part D in January 2006 represented a significant leap forward, since it provided coverage for outpatient drugs for Medicare patients for the first time. A high number of both patients and insurance providers are now involved in the program, as a result of strong patient enrollment.
Asthma Phenotypes A changing paradigm
Asthma Phenotypes A changing paradigm
An estimated 34 million people are diagnosed with asthma in the major markets. The disease can be broken down into various phenotypes, differentiated by severity, trigger, or predominant inflammatory type. These phenotypes may have important consequences for future approaches to treat asthma in a more targeted fashion, doing away with the one-size-fits-all approach.
Depression Novel drugs to grow third-line market
Depression Novel drugs to grow third-line market
Datamonitor believes that companies developing pipeline drugs for the depression market should concentrate resources on targeting third-line depression patients, a market with significant sales volume and few viable treatment options. GSK's gepirone ER is likely to be the first pipeline drug to enter the market and exploit this opportunity, with forecast sales of $615m in 2016.
Nosocomial Infections The need for new gram-negative drugs
Nosocomial Infections The need for new gram-negative drugs
In the US and Europe, an estimated 510% of patients are expected to develop an infection during their hospital stay. The four main types of infections that occur within the hospital setting are urinary tract infections, hospital acquired pneumonia, surgical site infections and blood-stream infections, accounting for approximately 35%, 15%, 14% and 10% respectively.
ePrescribing Infrastructure and Impact on the Healthcare Markets in the US and EU
ePrescribing Infrastructure and Impact on the Healthcare Markets in the US and EU
Technology has been used to either inform or expedite the prescribing process in most modern healthcare systems for over two decades. Recently, market forces - including greater regulatory intervention, increased investment from stakeholders and decreased resistance from end-users - have begun to converge to set the stage for widespread adoption of truly integrated ePrescribing solutions.
Atopic Dermatitis A high level of unmet need creates market opportunities
Atopic Dermatitis A high level of unmet need creates market opportunities
Atopic dermatitis is a skin disorder characterized by intense itch, dry skin and redness. Often considered a benign disease, it actually impacts very negatively on quality of life, sometimes more than psoriasis and diabetes. Through opinion leader interviews, Datamonitor has identified a high level of unmet need in atopic dermatitis treatment and believe that a number of market opportunities exist
Small Cell Lung Cancer and Malignant Mesothelioma Limited R&D activity provides opportunity for early-phase pipeline drugs
Small Cell Lung Cancer and Malignant Mesothelioma Limited R&D activity provides opportunity for early-phase pipeline drugs
SCLC accounts for one-fifth of all lung tumor types. More than 80,000 new cases are expected to be diagnosed in 2007 in the seven major markets, although it is set to decrease due to changing smoking habits. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe and Japan given the heavy use of asbestos in the 1970s and long latency period of the disease.
Esophageal Cancer Treatment paradigms need revolution not evolution
Esophageal Cancer Treatment paradigms need revolution not evolution
Globally, esophageal cancer is the ninth most common tumor type and seventh leading cause of cancer-related death, however, its incidence fluctuates widely depending on geographical area. While relatively uncommon in Western countries, 50% of patients still present with locally advanced unresectable or distant metastatic disease, where treatment is complicated and chances of a cure are reduced.
The Pharmaceutical Industry Key trends and strategic issues shaping the industry
The Pharmaceutical Industry Key trends and strategic issues shaping the industry
Datamonitor has identified the key trends and events that impacted the pharmaceutical market on a macro-environmental and corporate strategy level in 2006. These range from the continuation of long term trends such as the focus on cost containment to more recent impacts such as the effects of Medicare Part D and the increasing power of the Democratic part in the US.
eHealth for the Pharmaceutical Industry What companies need to know about trends in physicians and consumers use of the Internet
eHealth for the Pharmaceutical Industry What companies need to know about trends in physicians and consumers use of the Internet
An understanding of the present and future market trends surrounding eHealth is vital in order for the pharmaceutical industry to develop effective multi-channel marketing strategies. It is advisable for stakeholders to invest in targeted initiatives that meet the specific information needs and support the decision making processes of the large numbers of physician and consumer groups online.
HIV Change of guard
HIV Change of guard
The HIV market generated $7.4 billion of sales in 2005 and experienced a CAGR of 13.3% from 2001-2005, making it one of the fastest growing infectious diseases sub sectors. Despite the antiretroviral market's relative immaturity, many older flagship products such as Combivir are expected to lose patent protection before 2015.
Psoriasis Anti-TNF's lead another indication
Psoriasis Anti-TNF's lead another indication
There is no cure for psoriasis, which profoundly affects sufferers quality of life, physical and social functioning. There is a particular unmet need for effective long-term therapies for psoriasis. Prevalence is the highest of the autoimmune diseases at 16 million in 2006, but this is deceptive in terms of market size, as the treated and severe patient populations are comparatively small.
Osteoarthritis Market sees steady growth
Osteoarthritis Market sees steady growth
The 2004 withdrawal of Vioxx from the global market had a negative effect on the COX-2 class, with a 44% fall in Celebrex sales for osteoarthritis in 2005. However, as patients sought an alternative to the COX-2s, there was positive growth in traditional NSAIDs, non-narcotic analgesics, narcotic analgesics, corticosteroids and HA viscosupplements, leading to a 1.1% increase in total market value.
Atherosclerosis HDL ApoA-I Carotid MRI and 64-slice CT offer opportunities for future treatment
Atherosclerosis HDL ApoA-I Carotid MRI and 64-slice CT offer opportunities for future treatment
Atherosclerosis generally begins in childhood and manifests clinically in mid-to-late adulthood. While the mortality from atherosclerotic conditions has declined significantly, in developed countries cardiovascular disease accounts for nearly 50% of all deaths, and within the next 15-20 years, is projected to surpass infectious diseases to become the leading cause of death worldwide.
Multiple Sclerosis Disease-modifying efficacy and side effects guide treatment choice
Multiple Sclerosis Disease-modifying efficacy and side effects guide treatment choice
The disease-modifying drugs are considered by physicians to represent a significant advance for the management of MS. However, none is fully effective and there are problems with regards to side effects, dosing regimens and cost. Tysabri, a novel once-monthly drug is expected to be an improvement in terms of efficacy; however, there remains a concern over side effects and long-term safety.
Erectile Dysfunction Identifying product differentiation and patient segmentation strategies
Erectile Dysfunction Identifying product differentiation and patient segmentation strategies
The erectile dysfunction market grew 3.5% from 2005 to be worth $1.95 billion in 2005 and is almost entirely composed of sales from three brands: Viagra (sildenafil), Cialis (tadalafil) and Levitra (vardenafil). Despite the dominance of these products, several opportunities exist for a successful market entry.
Melanoma Lucrative commercial opportunities persist
Melanoma Lucrative commercial opportunities persist
Melanoma comprises just 5% of all skin cancers but it is the most deadly. In 2006, more than 100,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced patients remains below 20%.
Respiratory Syncytial Virus RSV A market yet to reach its full potential
Respiratory Syncytial Virus RSV A market yet to reach its full potential
RSV mostly causes upper respiratory tract infections (URTI), resulting in the common cold. However, in certain risk groups, RSV can cause more severe lower respiratory tract infections (LRTI) leading to bronchiolitis. These risk groups include elderly people, patients with underlying pulmonary or cardiac disease, premature infants, children under four years old and immunocompromised patients.
Taking CRM to the Next Level Web-assisted relationship and community-building for the pharmaceutical industry
Taking CRM to the Next Level Web-assisted relationship and community-building for the pharmaceutical industry
CRM is a business strategy by which a company seeks to maximize the value of its products by managing the customer relationship, with specific aims to boost customer retention and increase market share, while reducing the costs of sales, marketing and customer fulfillment. CRM is made necessary because of advances in Web-enabled technologies, which have changed the dynamics of sales and marketing.
The Pharmaceutical Company Outlook to 2011 Financial and Strategic Analysis of the Sales Outlook for Big Pharma Mid Pharma Japan Pharma and Biotech
The Pharmaceutical Company Outlook to 2011 Financial and Strategic Analysis of the Sales Outlook for Big Pharma Mid Pharma Japan Pharma and Biotech
Based on an analysis of 46 companies and 1,000+ products, Datamonitor forecasts that pharmaceutical industry ethical sales will increase at a modest 4.9% CAGR 200511. However, behind this industry average figure there are strategic segments of the market that offer double-digit growth rates through barriers against generic competition and the opportunity for aggressive indication broadening.
Biosimilars Benchmarking the key players With increasing regulatory clarity and high revenue potential interest in biosimilars increases
Biosimilars Benchmarking the key players With increasing regulatory clarity and high revenue potential interest in biosimilars increases
With increasing regulatory clarity and the expiries of key patents covering innovator biologics, the development of biosimilars for a range of recombinant protein classes is becoming increasingly attractive. Although many companies are targeting the market, 12 companies dominate. These include established generics companies, leading biosimilars developers, plus emerging biosimilar developers.
Obesity Lack of Reimbursement Limits Market Potential
Obesity Lack of Reimbursement Limits Market Potential
Datamonitor predicts a somewhat enthusiastic uptake of two agents currently in development by 2015. However, reimbursement is critical to the uptake of new medication, due to the high cost of therapy. If the reimbursable status is not achieved, the expansion of the market will not match the rate of growth of the obese population and the great potential of the obesity market will remain untapped.
Antibacterials Growth in resistance rates drives niche indications
Antibacterials Growth in resistance rates drives niche indications
The global antibacterial market, valued at $25.5 billion in 2005, is highly mature. Modest growth (CAGR 2001-2005: 5.1%) is fuelled by ageing, immunosuppression and emerging resistances, especially in the hospital and former niche markets (e.g. MRSA). The community market, however, is facing a value loss following the patent expiries of several blockbusters (e.g. Pfizer's Zithromax) in 2005.
Therapeutic Cancer Vaccines A turbulent path from bench to bedside
Therapeutic Cancer Vaccines A turbulent path from bench to bedside
Unmet needs across the cancer market remain high, with most therapies conferring low levels of specificity and high toxicity. Therapeutic cancer vaccines offer an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. However, despite years of R&D, a reproducible survival benefit has proved elusive, leaving the market wide open.
Alzheimer's Disease Prescribing trends indicate that neurologists are not adhering to guidelines
Alzheimer's Disease Prescribing trends indicate that neurologists are not adhering to guidelines
A lack of prescriber adherence to both marketing licenses and pharmacoeconomic guidelines represents both a challenge and opportunity for pharmaceutical companies marketing current Alzheimer's disease drugs. Indication expansion between disease severities may not be a viable commercial option; conversely, stricter guidelines by bodies such as the UK's NICE will not necessarily threaten the market.
Chinese Pharmaceutical Market Overview Regulatory reform and the evolving healthcare market provide opportunities in china
Chinese Pharmaceutical Market Overview Regulatory reform and the evolving healthcare market provide opportunities in china
The Chinese pharmaceutical market, although only positioned ninth globally, has experienced pronounced and rapid expansion in recent years, driven by the growth of both Chinese and Western manufacturers. Increasingly, there is a shift towards a research-based industry, focused on generating new, innovative therapies, supported by improving intellectual property regulations.
Antithrombotics Pipeline products to dampen the impact of patent expiries and cost containment initiatives
Antithrombotics Pipeline products to dampen the impact of patent expiries and cost containment initiatives
The ageing of the population will result in an increased incidence of coronary artery disease, heart failure and stroke. In addition to these epidemiological forces, the antithrombotics market will be sustained by the forthcoming launch of innovative novel agents whose sales revenue is expected to dampen the commercial impact of generic incursion in blockbuster proceeds.
Migraine Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries
Migraine Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries
After the launch of Trexima in 2007, triptan genericization coupled with a weak late-stage pipeline will result in a major shift in market dynamics, and will result in the migraine market value decreasing to $3.2 billion in 2015. The market remains receptive to superior prophylactics however, with innovation being essential for the progression of the acute market, post-triptan era.
Pricing and Reimbursement in Oncology Do payers believe oncology drugs offer good value
Pricing and Reimbursement in Oncology Do payers believe oncology drugs offer good value
The oncology market has shown remarkable growth in recent years, driven by the advent of targeted therapy and the high level of unmet needs in the disease, and it is poised for further expansion. While this will provide companies with opportunities, a key hurdle for novel cancer drugs will be the increasing pharmacoeconomic vigilance that prevails within cash-strapped healthcare systems.
Gynecological Cancers Niche opportunities in advanced disease
Gynecological Cancers Niche opportunities in advanced disease
Cases of endometrial cancer are set to rise in developed countries due to an increase in risk factors such as obesity. In contrast, while incidence of cervical cancer is set to decrease in developed countries following the implementation of anti-HPV immunization with Merck & Co's Gardasil and GlaxoSmithKline's Cervarix, it will remain a major cause of cancer-related death in the developing world.
Biosimilars Regulatory Issues Europe continues to make strides while the US lags behind
Biosimilars Regulatory Issues Europe continues to make strides while the US lags behind
The drive for increased cost savings by healthcare providers is increasing the focus on boosting the biosimilar market. With a regulatory approval pathway in place in Europe and substantial guidelines to support biosimilar development, the European biosimilars market is significantly more advanced than the US, where plans for a biosimilar regulatory approval pathway have stalled.
Drug Delivery Global Industry Guide
Drug Delivery Global Industry Guide
Datamonitor's Drug Delivery: Global Industry Guide is an essential resource for top-level data and analysis covering the drug delivery industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Biotechnology Global Industry Guide
Biotechnology Global Industry Guide
Datamonitor's Biotechnology: Global Industry Guide is an essential resource for top-level data and analysis covering the biotechnology industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Next-Generation Nutraceuticals Food and pharma convergence in disease prevention and personalized nutrition
Next-Generation Nutraceuticals Food and pharma convergence in disease prevention and personalized nutrition
Today, consumers are taking a more proactive approach to managing their health and the prevention of diet-related diseases, such as obesity, diabetes, cardiovascular and bone and joint diseases. Many of these diseases are at epidemic levels, and this combined with increasing patient power makes the prevention of these lifestyle diseases attractive markets for both the food and pharmaceutical industries to exploit.
Generics Global Industry Guide
Generics Global Industry Guide
Datamonitor's Generics: Global Industry Guide is an essential resource for top-level data and analysis covering the generics industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Optimizing Sales Force Effectiveness From quantity to quality
Optimizing Sales Force Effectiveness From quantity to quality
The environment in which pharmaceutical companies promote their products has become increasingly tough over recent years as a number of trends and factors drive changes. As the effects of shrinking pipelines and rising R&D costs impact companies, they are under increasing pressure to deliver greater productivity from their sales forces.
Inflammatory Bowel Disease Competition Increases for the Biologics
Inflammatory Bowel Disease Competition Increases for the Biologics
Ulcerative colitis and Crohn's disease are the primary constituents of Inflammatory Bowel Disease, which is estimated to affect approximately 1.8 million people in the seven major markets. Eight years after the launch of Remicade in Crohn's disease the next generation of anti-TNF's are poised for approval, but the anti-TNF class will soon be under attack from novel cytokine therapies.
Respiratory Tract Infections in the USA The demise of narrow-spectrum antibiotics
Respiratory Tract Infections in the USA The demise of narrow-spectrum antibiotics
In the US, approximately 88 million people are diagnosed with a respiratory tract infection in an average year. Of these, a total of 66 million patients suffer from one of the three major diagnoses: acute bacterial sinusitis (ABS), acute exacerbation of chronic bronchitis (AECB) and community-acquired pneumonia (CAP).
Emerging eHealth Technologies Key trends impacting the physician-patient relationship
Emerging eHealth Technologies Key trends impacting the physician-patient relationship
Internet-enabled information communication technologies, such as computers, mobile phones and PDAs have had a significant impact on the physician-patient relationship by allowing for the efficient and cost-effective management of large volumes of information, as well as by supporting communications between individuals that would otherwise be prohibited by time or geography.
Breakthrough Pain Fast-acting players will capture majority market share
Breakthrough Pain Fast-acting players will capture majority market share
In spite of generic Actiq competition, Cephalon’s reign of the breakthrough pain market will be secured in the short-term with sales of its follow-on brand Fentora. From 2008, however, a number of fast-acting analgesics will enter the arena and battle for market share; this and other growth drivers will see the market more than double from 2005 to reach an estimated $2.5 billion in 2016.
Osteoarthritis The Wait for a DMOAD Continues
Osteoarthritis The Wait for a DMOAD Continues
Osteoarthritis (OA) is characterized by the progressive destruction of articular joints and is a major cause of pain in Western populations. Osteoarthritis is the most common form of arthritis and severely impacts the physical function and day-to-day quality of life of an individual. It also impacts heavily on the economy and it is believed to cost the US alone an estimated $60 billion per year.
Pricing and Reimbursement in Japan Costly healthcare system inefficiencies increase the focus on healthcare cost containment
Pricing and Reimbursement in Japan Costly healthcare system inefficiencies increase the focus on healthcare cost containment
The government has relied on simple P&R tools to contain rising healthcare costs and provide a reasonable level of healthcare. However, factors such as a healthier elderly population are masking healthcare system inefficiencies, boosting healthcare costs and increasing the focus on cost containment. Although the rise in drug spending is slowing down, it remains a visible cost containment target.
Hormonal Contraceptives New directions in a competitive market
Hormonal Contraceptives New directions in a competitive market
The hormonal contraceptive market grew by 4.2% from 2004 to $5.0 billion in 2005. Market growth was driven in part by the strong uptake of Schering AG's Yasmin and Organon's NuvaRing which fulfill key strategies: additional indications and alternative delivery modes. Market growth is not expected to falter if companies employ these lifecycle strategies which promote uptake in a competitive market.
Regulator Perceptions in Cancer Evolving opinions about the oncology drug approval process
Regulator Perceptions in Cancer Evolving opinions about the oncology drug approval process
The oncology therapy area is unlikely to be spared from the heightened conservatism currently sweeping the regulatory environment. This is evidenced by the increased scrutiny with which the FDA appraises accelerated approval applications, particularly in light of the 2005 withdrawal of AstraZeneca's Iressa.
Non-Small Cell Lung Cancer The need to differentiate in an increasingly crowded and fragmented market
Non-Small Cell Lung Cancer The need to differentiate in an increasingly crowded and fragmented market
NSCLC comprises over 75% of all lung cancers. In 2006, more than 338,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient's remains below 12 months.
Innovation in Drug Delivery The future of nanotechnology and non-invasive protein delivery
Innovation in Drug Delivery The future of nanotechnology and non-invasive protein delivery
Drug delivery is one of the most dynamic and fast growing sectors of the pharmaceutical industry. The high level of innovation in this sector is evolving at a fast pace with products such as Pfizer’s inhaled insulin, Exubera, gaining US approval in January 2006.
Asthma COPD Targeted therapies on the horizon
Asthma COPD Targeted therapies on the horizon
The total asthma and COPD population in 2006 is estimated to be 44.8 million and 28.8 million respectively. While the majority of patients are well controlled with current therapies, the remaining unmet needs are twofold: first, to find better options for the 1.7 million patients with severe asthma; second, to identify effective anti-inflammatory drugs in COPD.
Epilepsy Pipeline drugs struggle to outshine their marketed predecessors
Epilepsy Pipeline drugs struggle to outshine their marketed predecessors
Slow generic uptake, reformulations, follow-on products and new market entrants will ensure steady long-term growth of the epilepsy market despite several high profile patent expiries. UCB has emerged as the number one epilepsy company, and is set to strengthen their epilepsy pipeline if the proposed acquisition of Schwarz is confirmed.
Colorectal Cancer Shaping the future dynamics of colorectal cancer management
Colorectal Cancer Shaping the future dynamics of colorectal cancer management
Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of Avastin and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years.
Molecular Targeted Cancer Therapies More drugs on the market more targets in the pipeline
Molecular Targeted Cancer Therapies More drugs on the market more targets in the pipeline
Cancer treatment continues to embrace the inclusion of molecular targeted therapies (MTT) into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge.
Stakeholder Insight Atrial Fibrillation Limited efficacy and poor safety lead to bleak outlook
Stakeholder Insight Atrial Fibrillation Limited efficacy and poor safety lead to bleak outlook
Datamonitor estimates that there are over 11 million atrial fibrillation patients in the seven major markets. Despite high unmet needs and limitations of all the current treatment options, achievement of regulatory approval is becoming increasingly difficult. This means that a very limited number of novel treatments are expected to be introduced in the near future.
Stakeholder Insight Supportive Care in Cancer Treatment Some first-generation products proving difficult to dislodge
Stakeholder Insight Supportive Care in Cancer Treatment Some first-generation products proving difficult to dislodge
Supportive care is used to prevent or treat the adverse effects that arise as a result of cancer treatment, particularly chemotherapy. While newer molecular targeted therapies do not exist without some toxicity, this is not as severe as that associated with traditional cytotoxics. A rising incidence of cancer worldwide will mean that supportive care market will increase both size and relevance.
Hip and Knee Replacement Market-Overview of the US and European markets - growth in a mature market
Hip and Knee Replacement Market-Overview of the US and European markets - growth in a mature market
The orthopedic joint replacement market is at a crossroads between time-tested conventional procedures and advanced implant materials and surgical techniques. Demand driven by an aging population and an increasing number of younger patients undergoing replacement procedures together with improved implant materials and surgical techniques are contributing to growth in this mature market.
Pricing and Reimbursement in Europe-Can the drive for cost effectiveness overcome cost containment?
Pricing and Reimbursement in Europe-Can the drive for cost effectiveness overcome cost containment?
Combined drug sales in the five major European markets represent the second-biggest market globally after the US. Unlike the US, which is dominated by a wide range of private payers, governments are the major payers in Europe. The monopsonistic nature of these markets provides governments with significant leverage and they use extensive P&R controls to contain spiralling healthcare costs.
Reformulation Strategies - Comparisons of Past and Future Reformulation Strategies
Reformulation Strategies - Comparisons of Past and Future Reformulation Strategies
Product lifecycle management (LCM) is an integral part of portfolio continuation and preservation. With R&D productivity stalling, and profit margins increasingly eroded by cost-containment initiatives, maximizing the return on investment (ROI) of in-line brands is a key objective for pharmaceutical companies.
Advanced Life Sciences Cethromycin - Phase III success should allow 'me-too' market entry and above-consensus growth
Advanced Life Sciences Cethromycin - Phase III success should allow 'me-too' market entry and above-consensus growth
Traditionally, the treatment of respiratory infections has largely involved antibiotics from the macrolide class. Advanced Life Sciences' cethromycin, along with Sanofi-Aventis' Ketek, is a ketolide, a second-generation class of macrolides with activity against bacterial strains resistant to macrolides. Data from two Phase III trials in community-acquired pneumonia are expected in early 2007.
Antihypertensives - New challenges for a maturing market
Antihypertensives - New challenges for a maturing market
Datamonitor expects the antihypertensive market to exceed $40bn by 2015 across the seven major markets, with novel treatments and the market-leading ARBs delivering much of this value. However, significant hurdles exist, and pharmaceutical companies need to carefully design marketing campaigns and pricing structures for their products.
Insulins - Inhalable insulins unlikely to become blockbusters
Insulins - Inhalable insulins unlikely to become blockbusters
Datamonitor expects the continuously growing prevalence of diabetes to drive growth in diabetes drug spending, potentially benefiting market uptake of novel insulin therapies. A set of novel, non-injectable insulins are poised to become available to patients in the next five years. By 2010, the market will thus have to absorb Pfizer's Exubera and at least three other inhalable insulins.
HIV - Extending treatment options
HIV - Extending treatment options
More people than ever are living with HIV and AIDS in North America and Western Europe. Over the next five years, a great variety of new HIV drugs are expected to reach the market early stage therapies will be simplified by new products that will transform the market. For those with few treatment options left, new pipeline products will redefine late stage therapy.
Rheumatoid Arthritis - Biologics battle up the treatment algorithm
Rheumatoid Arthritis - Biologics battle up the treatment algorithm
Rheumatoid arthritis is a debilitating and life-long disease that is estimated to affect approximately 5 million people in the seven major markets. The launch of anti-TNF products over six years ago and more recent novel target biologic therapies have added significantly to the treatment options, but have resulted in a crowded market for moderate to severe patients.
Palatin Technologies Bremelanotide - Competition and regulatory risk cloud potential
Palatin Technologies Bremelanotide - Competition and regulatory risk cloud potential
Palatin Technologies' bremelanotide (PT-141) is a novel melanocortin receptor agonist that is believed to be the only agent currently in development for the treatment of both erectile dysfunction (ED) and female sexual dysfunction (FSD).
Sirona Dental Systems - Likely struggle for impressive annual growth despite strong reputation and technology
Sirona Dental Systems - Likely struggle for impressive annual growth despite strong reputation and technology
Digital imaging products and CEREC form the basis for growth for Sirona Dental Systems, while accounting for nearly two-thirds of revenues, and will therefore be essential to the newly formed combination of Schick Technologies and Sirona.
Spectrum Pharmaceuticals Oral Satraplatin - Oral therapy to take share in second-line hormone-refractory prostate cancer market
Spectrum Pharmaceuticals Oral Satraplatin - Oral therapy to take share in second-line hormone-refractory prostate cancer market
There are no FDA-approved second-line chemotherapy options for hormone refractory prostate cancer, indicating a great unmet need, with a large potential market for an agent such as Spectrum's satraplatin, which could offer key advantages due to its oral administration profile.
Bipolar Disorder - New treatments for bipolar depression set to drive near-term growth
Bipolar Disorder - New treatments for bipolar depression set to drive near-term growth
Stimulated by sales of atypical antipsychotics for bipolar depression, and despite the launch of generic risperidone, the global bipolar disorder market will grow until 2011, when revenues will peak at $6.6 billion. The market will begin to decline thereafter owing to the launch of generic versions of the leading atypical antipsychotics, quetiapine, olanzapine, and ziprasidone from 2011 onwards.
ASCO Review Part I - A summary of highlights presented at the ASCO 2006 Annual Meeting
ASCO Review Part I - A summary of highlights presented at the ASCO 2006 Annual Meeting
ASCO features key presentations in the oncology area, and is generally the most important week of the year for oncology. Presents Datamonitor's comments on the most important events at the 2006 conference.
ASCO Review Part II - A summary of highlights presented at the ASCO 2006 Annual Meeting
ASCO Review Part II - A summary of highlights presented at the ASCO 2006 Annual Meeting
ASCO features key presentations in the oncology area, and is generally the most important week of the year for oncology. Presents Datamonitor's comments on the most important events at the 2006 conference.
Bausch and Lomb's Contact Lens Solution Withdrawal - ReNu MultiPlus likely to struggle in attempt to regain market share
Bausch and Lomb's Contact Lens Solution Withdrawal - ReNu MultiPlus likely to struggle in attempt to regain market share
In May 2006 Bausch & Lomb's ReNu with MoistureLoc contact lens solution was permanently withdrawn from markets worldwide due to an outbreak of a fungal eye infection. For a large market player, the loss of a new revenue driver and the negative publicity surrounding the event is likely to have a significant impact on future success, as well as implications for other companies in the sector.
Endo Pharmaceuticals Lidoderm - Physician survey indicates increased use likely to fuel above-consensus sales growth
Endo Pharmaceuticals Lidoderm - Physician survey indicates increased use likely to fuel above-consensus sales growth
Launched in the US in 1999 as the only topical lidocaine patch, Lidoderm has demonstrated very strong growth year-on-year, with annual growth of 114% in 2003, 73% in 2004, and 36% in 2005. Lidoderm’s continued growth in both labeled and off-label indications is highly important to the company’s future success.
Indevus Pharmaceuticals Sanctura XR - Last-to-market entrant unlikely to make an impact in crowded OAB market
Indevus Pharmaceuticals Sanctura XR - Last-to-market entrant unlikely to make an impact in crowded OAB market
The lack of differentiation between overactive bladder agents has led manufacturers to turn to large-scale marketing efforts in an attempt to gain market share. Given the relatively small marketing capabilities of IDEV and Esprit, they may have difficulty penetrating high-prescribing urology and primary care practices compared to its larger rivals, thus slowing Sanctura XR's near-term potential.
Renovis NXY-059 - Safety profile and unmet need could drive approval
Renovis NXY-059 - Safety profile and unmet need could drive approval
Renovis and AstraZeneca's NXY-059 is viewed as the most promising neuroprotectant currently in development for stroke, however, much of its potential is dependent upon its ability to demonstrate a benefit in the recently enrolled SAINT-II trial.
Santarus Zegerid - Fast-acting formulation gaining momentum in GERD
Santarus Zegerid - Fast-acting formulation gaining momentum in GERD
Following the lackluster 2004 launch of an oral suspension formulation of Santarus' lead product, Zegerid (a fast-acting proton pump inhibitor) much of Santarus' future success is tied to the commercial potential for the recently launched Zegerid oral capsule formulation to drive near-term revenues.
Antidiabetics - Patent expiries and cost containment initiatives balanced by pipeline products
Antidiabetics - Patent expiries and cost containment initiatives balanced by pipeline products
The diabetes epidemic has contributed to growth in the antidiabetics market over the past few years. Since the prevalence of diabetes continues to increase, the market will further expand. While early therapy is dominated by generically available agents, and the later stages by insulin, the number of unmet needs in the diabetes treatment warrants that novel agents will have a place in the market.
Pharmaceutical Outsourcing Part 2 - An Introduction to Drug Discovery Strategies
Pharmaceutical Outsourcing Part 2 - An Introduction to Drug Discovery Strategies
The pharma industry is facing a crisis over R&D productivity, as reflected by the low level of new drug approvals despite companies investing the highest ever amounts in R&D. As a result, companies are seeking novel ways to drive growth, with many opting to increase their reliance on third parties - through licensing, collaborative and outsourcing agreements - in an attempt to achieve this.
Patients as Consumers - Understanding the Increasing Consumer Level of Influence in Healthcare
Patients as Consumers - Understanding the Increasing Consumer Level of Influence in Healthcare
According to Datamonitor's eHealth Consumer Insight Survey, consumers in the US, Western EU and Japan access search engines more frequently than any other type of online or offline information resource when looking for health information. As a result, consumers' requests for medication based on information obtained online have become an increasingly influential factor in the prescribing process.
Orthopedics - Global Industry Guide
Orthopedics - Global Industry Guide
Datamonitor's Orthopedics: Global Industry Guide is an essential resource for top-level data and analysis covering the orthopedics industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Asthma - COPD - ICS - LABA combinations continue to dominate
Asthma - COPD - ICS - LABA combinations continue to dominate
The respiratory market will continue to experience strong growth for the next 6 years, driven by the expansion of sales in existing classes, the launch of major new products with safety and convenience advantages, and the results of several landmark studies. Despite patent expiries of three leading products, from 2010, the market will avoid a collapse like the one seen for oral antihistamines.
Antidyslipidemics - Branded statins beware, generics are amongst you
Antidyslipidemics - Branded statins beware, generics are amongst you
Commercial Insight: Antidyslipidemics explores current trends and key future issues in the management of dyslipidemia and the effects of generic competition and healthcare reforms on the main drug classes in this market. The growth potential of the leading classes is discussed, and case studies are used to highlight possible strategies to maximize future growth for lipid management franchises.
Neuropathic Pain - A Plethora of Patient Segmentation and Product Differentiation Opportunities
Neuropathic Pain - A Plethora of Patient Segmentation and Product Differentiation Opportunities
Neurontin (gabapentin) has finally been knocked off the top spot as a result of fierce generic incursion. However, Pfizer's follow-on Lyrica (pregabalin), Lilly's Cymbalta (duloxetine) and Endo/Elan's Lidoderm (lidocaine patch 5%) are re-establishing market growth and laying the groundwork for new entrants.
eCME-Leveraging Online Continuing Medical Education as a Channel of Influence
eCME-Leveraging Online Continuing Medical Education as a Channel of Influence
The changing nature of CME has caused the pharmaceutical industry to reassess its investment in CME. While more restrictive guidelines and increased oversight may persuade many companies to decrease their investments in CME, Datamonitor recommends that stakeholders seize this opportunity to invest in educational programs that produce positive results in physician behavior and patient health.
Breast Cancer - A diverse and increasingly crowded pipeline
Breast Cancer - A diverse and increasingly crowded pipeline
Breast cancer is the leading cause of cancer-related mortality among women worldwide. In 2006, more than 447,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type. Despite recent drug approvals in the adjuvant and metastatic setting, the overall survival remains below five years.
Cancer Overview  Emerging Therapeutic and Commercial Opportunities
Cancer Overview Emerging Therapeutic and Commercial Opportunities
The 11 tumor types covered in this report will account for over 2.3 million new cases of cancer in 2006 in the seven major pharmaceutical markets. Despite the emergence of targeted therapies, major unmet needs remain. NSCLC and breast cancer attract the highest R&D interest, but niche tumors with high unmet needs are gaining significant interest from pharmaceutical and biotech companies.
Schizophrenia
Schizophrenia
The global schizophrenia market will continue to grow until 2010, when revenues will reach $3.8 billion. However, despite the launch of numerous pipeline schizophrenia drugs, the market will begin to decline thereafter owing to the US launch of generic risperidone in 2007, followed by generic versions of olanzapine, quetiapine and ziprasidone from 2011 onwards.
Parkinson's Disease - Review of Key Commercial Opportunities in the Symptomatic Treatment Market
Parkinson's Disease - Review of Key Commercial Opportunities in the Symptomatic Treatment Market
Parkinson's disease (PD) is a progressive, degenerative condition of the central nervous system (CNS), caused by the degeneration of dopaminergic neurons in the substantia nigra of the midbrain. The PD market grew by 6.9% to $1.8 billion between 2004 and 2005. In the absence of conclusive evidence for a neuroprotective compound, the focus on the market remains on symptomatic treatment.
From blockbuster to nichebuster - Niche therapies drive future drugs growth and incentivize R&D investment over sales spending
From blockbuster to nichebuster - Niche therapies drive future drugs growth and incentivize R&D investment over sales spending
> Overview of the role that blockbusters have played in shaping and driving market growth

 

> Identification of which niche disease markets to target, to maximize value from the nichebuster model

 

> Examination of how a range of different drivers such as regulatory initiatives are incentivizing the nichebuster model

 

> Identification of trends underlying R&D collaborations or licensing deal activity in allowing Big Pharma to access novel technologies and markets
Health Care Equipment & Supplies: Global Industry Guide
Health Care Equipment & Supplies: Global Industry Guide
Datamonitor's Health Care Equipment & Supplies: Global Industry Guide is an essential resource for top-level data and analysis covering the health care equipment & supplies industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Ovarian Cancer - Growing importance as secondary indication for targeted therapies
Ovarian Cancer - Growing importance as secondary indication for targeted therapies
Despite being the most common cause of death from gynecological tumors, ovarian cancer has not traditionally attracted the same level of R&D interest as other female cancers. Nevertheless, nearly 60,000 cases of ovarian cancer being diagnosed in the seven major markets each year is, by no means, small and therefore, it remains an important secondary indication for existing and pipeline drugs.
Commercial Insight Top 20 Cancer Therapeutics
Commercial Insight Top 20 Cancer Therapeutics
The Top 20 cancer therapeutics generated sales of $20.1 billion in 2005 across the seven markets, set to reach $27.4 billion by 2015. Cytotoxics currently constitute the majority, due to their long history in oncology and their key role in current treatment. By 2015, the majority of the Top 20 will consist of targeted therapies, whose place in cancer therapy will become increasingly established.
Systemic Lupus Erythematosus - On the Verge of a Breakthrough
Systemic Lupus Erythematosus - On the Verge of a Breakthrough
Systemic Lupus Erythematosus is a chronic, life-long and potentially fatal autoimmune disease characterized by multiple system distress and unpredictable flares. High unmet need makes this an attractive market but dispute over patient numbers and clinical trial difficulties are significant hurdles for new entrants to overcome.

 

Commercial Insight: Transplantation
Commercial Insight: Transplantation
In 2005, over 50.000 solid organ transplants were conducted in the seven major markets. In order to prevent the patient's immune system from rejecting the transplanted organ, immunosuppression therapy is required for the lifetime of the graft with a base maintenance drug (either Calcineurin- or mTOR inhibitors) and adjunctive therapies (antimetabolites, steroids).
Pipeline Insight: Hepatitis C - Protease inhibitor to drive market expansion
Pipeline Insight: Hepatitis C - Protease inhibitor to drive market expansion
An estimated 10 million people in the seven major markets have chronic HCV. The current standard of care, pegylated interferon (Peg-IFN) plus ribavirin (RBV), achieves long-term disease remission in approximately half of those receiving treatment. More efficacious therapies are required to improve treatment success in difficult-to-treat patients, in particular patients with HCV genotype 1.
Pharmaceutical Outsourcing Part 1: Contract Manufacturing Strategies - Offshoring is not the only option to drive productivity and efficiencies
Pharmaceutical Outsourcing Part 1: Contract Manufacturing Strategies - Offshoring is not the only option to drive productivity and efficiencies
The dynamics of the contract manufacturing landscape in the pharmaceutical industry are changing. With the increasing globalization of the contract manufacturing market, particularly regarding on-patent biologics and APIs, companies need to position themselves to be able capture the cost savings Asian countries have to offer.
Global Generics Guide: Part 2 - Benchmarking country markets and strategic issues
Global Generics Guide: Part 2 - Benchmarking country markets and strategic issues
The generics market is undergoing significant change, with intense merger and acquisition activity, a raft of upcoming patent expiries and new legislation being enacted to promote generic prescription in the major markets. In addition, key issues, such as authorized generics, the first biosimilars approvals and increasing competition within the market are also affecting growth dynamics.
Pricing and Reimbursement in the US: Innovation and robust pharmacoeconomic analysis are key
Pricing and Reimbursement in the US: Innovation and robust pharmacoeconomic analysis are key
The US is the leading global drugs market in terms of sales and profit margin. However, drug companies are facing an unprecedented number of challenges in maintaining revenue growth: fewer drugs are being approved, a wide number of blockbusters are facing patent expiry, and payers are implementing stringent cost-containment policies in the face of sky-rocketing healthcare costs.
Mid Pharma Sector: In-licensing and other externalization strategies
Mid Pharma Sector: In-licensing and other externalization strategies
Mid Pharma companies are EU/US based pharmaceutical companies with 2005 annual revenues of <$10bn. An integral component of the Mid Pharma business model is securing access to promising new drugs through in-licensing and acquisition.
Management of Urinary Incontinence and Overactive Bladder - A Global Overview
Management of Urinary Incontinence and Overactive Bladder - A Global Overview
Although there are many marketed treatments for overactive bladder, there are few available for stress urinary incontinence or interstitial cystitis. Furthermore, despite available treatments for overactive bladder, many are associated with side effects leading to poor treatment compliance. With significant unmet needs remaining in these markets, there are clear opportunities for new entrants.
Cancer Biomarkers: Enhancing diagnostic, therapeutic and developmental strategies
Cancer Biomarkers: Enhancing diagnostic, therapeutic and developmental strategies
The current focus on biomarker discovery is a result of an improved understanding of the biologic basis for carcinogenesis. The increasing number of potential drug targets and a plethora of diverse, new developmental agents have stimulated the search for biomarkers that can reduce the time, cost and attrition rates prevalent in oncology drug development.
Antiarrhythmics - RSD1235 in a class of its own
Antiarrhythmics - RSD1235 in a class of its own
Datamonitor believes that RSD1235 (iv) has the potential to have a significant impact on the treatment of atrial fibrillation. In addition, P&G's Stedicor and Sanofi-Aventis' Multaq also offer advances on current treatments, with improvements in efficacy and safety therein.
Directed Molecular Evolution: Product lifecycle management for biologics
Directed Molecular Evolution: Product lifecycle management for biologics
Biologics are forecast to be the fastest growing segment of the pharmaceutical market out to 2010 (12.2% CAGR). However, biologics face the emergence of bio-similars and increasing numbers of competitor products, both factors that intensify the commercial need for next-generation biologics with superior product characteristics. DMEa method for optimizing biologicsdirectly addresses this need.
'Big Pharma' Turns to Biologics for Growth to 2010 - Financial and strategic segmentation of the 'Big Pharma' sector by drug technology
'Big Pharma' Turns to Biologics for Growth to 2010 - Financial and strategic segmentation of the 'Big Pharma' sector by drug technology
'Big Pharma' (non-biotech companies with annual revenues >$10bn) has historically focused on small molecules. However, this is set to change, with around 60% of revenue growth forecast to come from biologic products (therapeutic proteins and monoclonal antibodies): by 2010, annual sales of biologics will have increased by $26bn, compared to a $13bn increase for small molecules.
Global Generics Guide: Benchmarking the key players
Global Generics Guide: Benchmarking the key players
The generics industry has undergone significant change over the last five years, with a wave of consolidation altering the competitive landscape. Indeed, the intense merger and acquisition activity has lead to more diverse companies, both on a product level and geographically, with pure generics companies becoming increasingly rare.
Parallel Trade in Europe and the US: The challenge facing pharma
Parallel Trade in Europe and the US: The challenge facing pharma
Since the beginning of this decade, parallel trade levels of pharmaceutical drugs in the US and Europe have risen to some of the highest levels ever seen, exerting additional pressure on the profitability of pharmaceutical companies. As a result, it has become ever more important for pharmaceutical companies to take action to limit the impact of this.
Dry Overactive Bladder - A Precursor to 'Wet Overactive Bladder'
Dry Overactive Bladder - A Precursor to 'Wet Overactive Bladder'
Dry Overactive Bladder (dry OAB) is considered part of the overactive bladder syndrome. However, unlike wet overactive bladder (or urge urinary incontinence), it is normally only associated with urinary urgency and frequency, and not incontinence. Even so, recent studies suggest that these symptoms bother patients, with unpredictable urges disrupting daily activities and quality of life.
Urge Urinary Incontinence - Poor Differentiation Limiting New Product Uptake
Urge Urinary Incontinence - Poor Differentiation Limiting New Product Uptake
Urge urinary incontinence (UUI) is a relatively common disorder which can affect all age groups but becomes increasingly prevalent with old age. Although several pharmacological therapies are available for treating this distressing condition, patients' reluctance to present to a physician and incorrect diagnosis of the different overactive bladder subtypes limit the potential of this market.
Stress Urinary Incontinence - Opinion Divided on Divided on Drug Therapy
Stress Urinary Incontinence - Opinion Divided on Divided on Drug Therapy
Stress urinary incontinence (SUI) is the most common type of urinary incontinence in women. Up until recently there were no globally developed or widely approved pharmacological treatments for this disorder leaving women with few treatment optionsnon-invasive (e.g. pelvic floor exercises) or invasive (i.e. surgery) non-pharmacological therapy.
Mixed Urinary Incontinence - An Opportunity for Novel Drug Therapy
Mixed Urinary Incontinence - An Opportunity for Novel Drug Therapy
Mixed Urinary Incontinence (MUI) affects over 10% of women, with women suffering from unpleasant symptoms of both urge urinary incontinence (UUI) and stress urinary incontinence (SUI). At present, no pharmacological agent is able to effectively treat the symptoms of both UUI and SUI.
Interstitial Cystitis - Few Treatments, Poor Outcome
Interstitial Cystitis - Few Treatments, Poor Outcome
Interstitial cystitis (IC) is considered a rare disorder and poor understanding of the underlying causes of the disorder have made diagnosis and management difficult. Moreover, this has impacted on the development of effective drugs for this disorderthere are few available treatments for IC and as a result, significant unmet needs exist.
Immunotherapy in Allergic Rhinitis - Moving away from injections
Immunotherapy in Allergic Rhinitis - Moving away from injections
Allergic rhinitis affects between 15% and 20% of the population in the seven major markets. Currently available treatments focus on symptom relief; however, a significant number of allergic rhinitis patients with uncontrolled symptoms remain. Shorter, safer, and more convenient therapies currently in development may lead to a substantial market expansion.
Personalizing Disease Management Through Technology Solutions - Part II - Vendor Landscape
Personalizing Disease Management Through Technology Solutions - Part II - Vendor Landscape
Disease management is not a new concept in the healthcare industry and despite the heterogeneity that characterizes this field, such programs are becoming an important part of the healthcare sector. As the vendor industry continues to evolve through mergers and acquisitions, technology and consumer forces will shape future disease management offerings.
Metabolic Syndrome - Multiple definitions complicate treatment
Metabolic Syndrome - Multiple definitions complicate treatment
Datamonitor estimates that there are nearly 86 million Metabolic Syndrome patients in the six major markets. Although the patient pool in need of treatment for Metabolic Syndrome is large, the lack of an approved indication for Metabolic Syndrome, the lack of a consensus definition and the aversion of physicians to pharmacotherapy limit the size of the Metabolic Syndrome market, considerably.
Major Depressive Disorder - Duloxetine - Fulfilling An Unmet Need?
Major Depressive Disorder - Duloxetine - Fulfilling An Unmet Need?
Major Depressive Disorder (MDD) is estimated to affect over 34 million individuals yearly across the seven major markets. Only a fraction of this patient population is treated adequately, resulting in lost productivity, unnecessary patient suffering and unfulfilled revenue potential for manufacturers.
Kidney Transplantation - Switching to calcineurin inhibitor-free immunosuppression
Kidney Transplantation - Switching to calcineurin inhibitor-free immunosuppression
In 2005, around 30,000 renal transplants were conducted in the seven major markets. In order to prevent the patient’s immune system from rejecting the transplanted organ, daily immunosuppression therapy is a necessity for the lifetime of the graft with a base maintenance drug (cyclosporine, tacrolimus, sirolimus) combined with adjunctive therapies (azathioprine, mycophenolate mofetil, steroids).
Non-Small Cell Lung Cancer Avastin to lead the market
Non-Small Cell Lung Cancer Avastin to lead the market
Non-small cell lung cancer comprises over 75% of all lung cancers. In 2006, more than 338,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the overall survival of NSCLC patients remains below 12 months.
Gastric Cancer - Targeted Therapies Home In On a Neglected Tumor Type
Gastric Cancer - Targeted Therapies Home In On a Neglected Tumor Type
Despite declining incidence rates, gastric cancer remains the second most common tumor type and second cause of cancer-related death worldwide. Gastric cancer occurs nearly five times more frequently in Japan than in the West. While early diagnosis and encouraging survival rates are common in Japan, the disease confers greater mortality in the West, thus representing a significant health burden.
Acute Leukemias - Persistent unmet needs confer significant commercial opportunity
Acute Leukemias - Persistent unmet needs confer significant commercial opportunity
While existing treatment strategies for adult acute leukemia may yield satisfactory remission- induction rates, a major clinical concern is the high rate of disease relapse despite attempts to optimize post-remission consolidation therapy. This is acutely problematic among elderly patients who are frequently unable to tolerate the rigors of more intensive treatment approaches.
Osteoarthritis - Preconceptions Damage Awareness and Treatments
Osteoarthritis - Preconceptions Damage Awareness and Treatments
Osteoarthritis offers a very attractive commercial target in terms of patient potential, and the explosion in new disease modifying drugs in rheumatoid arthritis has highlighted the possibilities for OA. However, controversy in the Cox-2 class, preconceptions about alternative treatments and even debate around the definition of OA make this a more difficult market to break into than first thought.
Anxiety Disorders - A decade of declining revenues
Anxiety Disorders - A decade of declining revenues
The global anxiety disorders market is set to decline from $4.5 billion in 2006 to $2.6 billion by 2015 (CAGR 2006 15 -6.0%). This will be primarily due to the launch of numerous generic anxiety drugs from 2006 onwards, which will offset the revenue growth derived from existing drugs seeking additional anxiety indications, and the launch of several novel anxiety drugs.
Antihypertensives - Weak pipeline leaves innovation to Novartis
Antihypertensives - Weak pipeline leaves innovation to Novartis
Despite modest improvements in blood pressure control, effective blood pressure control for all still seems to be an elusive goal. As such, the promotion and use of combination therapies has increased, explaining much of the current R&D activity in this area where many developers are studying novel combinations of currently marketed drugs rather than discovering innovative treatments
Acute Stroke - Considerable unmet need is balanced by substantial commercial risk
Acute Stroke - Considerable unmet need is balanced by substantial commercial risk
Stroke is one of the top three causes of death and its incidence in the seven major markets is expected to increase in the next ten years because of an aging population. Long term disability caused by stroke is a major economic burden on healthcare systems, current treatment options are limited and general awareness of stroke is poor.
The Pharmaceutical Industry - Key events and trends shaping its current status and future direction
The Pharmaceutical Industry - Key events and trends shaping its current status and future direction
Despite a tough year in 2005 in terms of the regulatory environment and public opinion, with the withdrawal of Vioxx still at the forefront of peoples' minds, a number of leading pharmas continued to drive impressive growth. Biologicals continued to lead the market in terms of growth with Genentech's cancer focused portfolio driving the fastest growth in 2005 and forecast to do the same in 2006.
Urinary Incontinence and Overactive Bladder - The Perspective of the Continence Nurse in the US
Urinary Incontinence and Overactive Bladder - The Perspective of the Continence Nurse in the US
Urinary incontinence and overactive bladder disorders are estimated to affect more than 10% of the female population. However, presentation, diagnosis and treatments rates are poor. In the US, the employment of Continence Nurses provides an ideal opportunity to ensure that patients are able to gain access to expert advice and treatment.
Stakeholder Opinions - Sepsis - Under reaction to an overreaction
Stakeholder Opinions - Sepsis - Under reaction to an overreaction
Personalizing Disease Management through Technology - Part 1
Personalizing Disease Management through Technology - Part 1
Disease management (DM) is becoming an important topic not only within the US health care agenda, but also globally. Forces driving the disease management market include a world-wide aging population and increasing healthcare costs. Additionally, because ROI studies on DM programs have been limited or inconclusive these programs have failed to gain significant traction.
The eHealth Market in Italy and Spain: Key Trends in Physician Channels of Influence
The eHealth Market in Italy and Spain: Key Trends in Physician Channels of Influence
The majority of physicians surveyed in Italy and Spain access the Internet for work-related purposes five hours per week or less. The viability of using Internet-enabled applications to reach physicians is dependent largely on both the level of access physicians have to an Internet connection both at work and at home, as well as the time physicians have available to go online during their workday.

 

Monoclonal Antibodies in Asthma: The choice between life and breath?
Monoclonal Antibodies in Asthma: The choice between life and breath?
Although only 5% of asthma suffers have severe asthma, these patients account for a disproportionately high percentage of healthcare spending, as asthma-related hospitalizations and emergency room visits are two of the costliest outcomes, which highlights the significant unmet need in this market.
Stakeholder Opinions: Cystic Fibrosis
Stakeholder Opinions: Cystic Fibrosis
Approximately 50,000 cystic fibrosis patients worldwide still await a cure of their disease (WHO, 2004). Gene therapy experienced its first failure in 2005 therefore focusing attention on new strategies such as ion channel modulation. In the meantime, the administration of current drugs is improving, which should advance general patient-compliance.
Maximizing eHealth Tools for Caregivers: Cultivating Long-Term Relationships
Maximizing eHealth Tools for Caregivers: Cultivating Long-Term Relationships
Caregivers are taking a more proactive role in providing healthcare to themselves and others, using online tools and services to find information, and influencing physician prescribing decisions by requesting particular medication or discussing specific products. By providing online resources for caregivers, pharma companies can increase brand loyalty among caregivers, and potentially, physicians.
Pulmonary Arterial Hypertension - A small market gets big attention
Pulmonary Arterial Hypertension - A small market gets big attention
Datamonitor expects the global pulmonary arterial hypertension (PAH) market to grow from $636m in 2004 to just over $2 billion by 2014, as new product and formulation launches in the US and a healthy late-stage pipeline drive sales growth. With this increased interest, combined with increased awareness and R&D activity, treatment for this orphan disease is set to enter a new era
The Changing Patient-Physician Relationship Part 2 the Physician's Perspective
The Changing Patient-Physician Relationship Part 2 the Physician's Perspective
The Internet has played a key role in changing the patient-physician relationship. Time constrains and productivity pressures are driving physicians to the Internet to keep abreast of medical knowledge. At the same time, physicians are becoming accustomed to the role of patients as consumers. Physician behavior is changing in response to this consumerism trend in healthcare.
Optimizing Sales Force Effectiveness: Using eHealth Applications to Improve the Quality of Physician Interactions
Optimizing Sales Force Effectiveness: Using eHealth Applications to Improve the Quality of Physician Interactions
Gaining access to influential healthcare professionals is difficult because physicians often do not have time to see drug reps during the working day. Furthermore, drug reps often fail to make the most of the limited time they do have with prescribers. Over time this has caused drug reps to lose influence to patient requests during the prescribing process.
Pharmaceuticals: Global Industry Guide
Pharmaceuticals: Global Industry Guide
Datamonitor's Pharmaceuticals: Global Industry Guide is an essential resource for top-level data and analysis covering the pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Commercial Perspectives: Drug Treatment in End-Stage Renal Disease - The Price of Failure
Commercial Perspectives: Drug Treatment in End-Stage Renal Disease - The Price of Failure
Increased prevalence of diabetes, obesity, and cardiovascular disease, all causal factors of renal disease, drives growth of the end-stage renal disease (ESRD) sector. On average, an ESRD patient uses >$7,000 of drugs/year, representing a significant opportunity for pharmaceutical companies in treating the symptoms, comorbid conditions and treatment side effects of ESRD.
Stakeholder Perspectives: Influenza Vaccines - Flying back Into Flu
Stakeholder Perspectives: Influenza Vaccines - Flying back Into Flu
Influenza is a highly infectious disease which globally infects 10-20% of the population every year causing up to 500,000 deaths. Although all persons are at risk, the elderly and the young are the most vulnerable. For decades, trivalent prophylactic vaccines produced in chicken eggs have been used to reduce the burden of influenza with approximately 300 million doses produced globally.
Commercial Insight: Antidyslipidemics - Statins Hit the Brakes on Market Growth
Commercial Insight: Antidyslipidemics - Statins Hit the Brakes on Market Growth
The antidyslipidemics market is driven by the statins, which account for 87% of it. However, as many statins are expected to face patent expiry in the coming decade their role is expected to change from a driver to that of almost a resistor. Manufacturers are looking to novel products to protect their franchise, such as Pfizer's atorvastatin/torcetrapib.
Stakeholder Opinions: Renal Cell Carcinoma - Novel Targeted Treatments to Fill the Void
Stakeholder Opinions: Renal Cell Carcinoma - Novel Targeted Treatments to Fill the Void
A meager 20% of metastatic RCC tumors respond to standard cytokine therapy, thus rendering 80% of advanced RCC patients without any effective treatment. Further, with up to 50% of stage one to three patients relapsing following nephrectomy and an increasing incidence of this disease, RCC represents a lucrative commercial opportunity for the developers of novel, effective pharmacotherapy.
Commercial Insight: Antihypertensives - Two Years to Shape the Market?
Commercial Insight: Antihypertensives - Two Years to Shape the Market?
Datamonitor expects the antihypertensive market to exceed $50bn by 2014 across the seven major markets, with novel treatments and the market-leading ARBs delivering much of this value. However, significant hurdles exist, and pharmaceutical companies need to be savvy regarding marketing and pricing structures for their products, as only the most cunning and aggressive companies look set to survive.
Stakeholder Insight: Orthopedic Postoperative Pain - Old Habits Hurt Market Potential
Stakeholder Insight: Orthopedic Postoperative Pain - Old Habits Hurt Market Potential
Postoperative pain can be caused by many different surgical procedures, each involving a variety of complications and physician specialties. Pain is a subjective experience for patients and it would seem that prescribing is driven by physicians' subjective preferences. Patients frequently have to suffer with their pain and request treatment before medication is initiated.
Stakeholder Insight: Hepatitis in China - Liver Let Die?
Stakeholder Insight: Hepatitis in China - Liver Let Die?
Hepatitis is a major health problem in China, which is home to one third of hepatitis B patients and one quarter of hepatitis C patients globally. HBV vaccination, together with HBV and HCV screening have helped to reduce transmission, but continued transmission from mother to child (for HBV) and transmission via blood transfusions (HCV) means that HBV and HCV are likely to remain a problem.
Commercial Insight: Disease Modification in Rheumatoid Arthritis - The Biologics Boom
Commercial Insight: Disease Modification in Rheumatoid Arthritis - The Biologics Boom
The global Rheumatoid Arthritis (RA) market has experienced extraordinary growth over the last decade. This market valued at $4.14 billion in 2004, shows no hint of decline. The explosion in new disease modifying drugs since the late 1990's has resulted in a competitive and rapidly evolving market. However, the recent events in the COX-2 market will continue to impact all arthritis drugs.
Pipeline and Commercial Perspectives: Insomnia
Pipeline and Commercial Perspectives: Insomnia
Until recently, the insomnia market has been dominated by Ambien, Sonata, and Imovane, and the older hypnotics such as benzodiazepines. However, the global insomnia market is set to grow from $3.7 billion in 2005 to $5.5 billion by 2014 (CAGR, 5.6% 200514), driven primarily by the launch and up-take of Lunesta, Rozerem and Ambien CR as well as pipeline drugs from 2006 onwards.

 

Commercial Insight: Generic Cancer Market - New Legislation and a Wave of Patent Expiries to Transform the Market
Commercial Insight: Generic Cancer Market - New Legislation and a Wave of Patent Expiries to Transform the Market
Over the next 10 years a significant number of key oncology products, some with blockbuster status, will lose patent protection, thus exposing billions of dollars to generic erosion. While obviously a major threat to the key pharmaceutical players and sales of their branded products, this presents significant opportunities to potential generic manufacturers.
Marketing Drugs in an Era of Pharmacovigilance - Best practice after drug safety scares and the implications for the future
Marketing Drugs in an Era of Pharmacovigilance - Best practice after drug safety scares and the implications for the future
There have been several drug safety scares over the last five years, most notably the withdrawal of Vioxx and the problems with the SSRI antidepressants. With growing public and physician awareness of safety issues, and new PhRMA guidelines for direct-to-consumer advertising drawn up in response to the withdrawal of Vioxx, companies face new challenges when planning future promotional campaigns.
Opioid Abuse - Hooked on Generics?
Opioid Abuse - Hooked on Generics?
Opioid abuse is a growing medical challenge, yet few developments have been made in its treatment in recent years. The market requires clarification of the goals of therapy - to remove the addictive behavior or to just manage the addiction and modify the impact on the abuser's life?
Stakeholder Insight: COPD - Another Reason to Quit
Stakeholder Insight: COPD - Another Reason to Quit
COPD is a deadly disease of the elderly, with patients suffering years of progressive discomfort and disability with no pharmacological interventions able to slow the progressive decline in lung function. A large, increasing patient population demands the development of truly novel COPD-focused therapies which must be coupled with improved disease awareness and diagnosis.
Juvenile Arthritis - A Niche In The Market
Juvenile Arthritis - A Niche In The Market
Juvenile arthritis is the next indication due for approval for blockbuster biologic therapies Remicade (infliximab) and Humira (adalimumab). Pediatric rheumatology is a growing specialty that offers high unmet need in terms of effective well-tested treatments.
Therapeutic Vaccines: More Trials and Tribulations
Therapeutic Vaccines: More Trials and Tribulations
Therapeutic vaccines have faced numerous setbacks in recent years. The only three vaccines to reach the market have had insignificant sales, while the pipeline has seen numerous high-profile failures and no new product launches in three years.
Inhalable Drug Delivery: Industry Holds its Breath in Anticipation of Systemic Success
Inhalable Drug Delivery: Industry Holds its Breath in Anticipation of Systemic Success
Currently driven by the needs of the expanding respiratory market, the inhalable drug delivery sector has also been invigorated by the promise of growth through the systemic delivery of drugs via the lungs as the first inhalable insulin nears the market.
Stakeholder Insight: Hypertension - Multiple Layer of Therapy Cover all Eventualities
Stakeholder Insight: Hypertension - Multiple Layer of Therapy Cover all Eventualities
Hypertension is a deadly disease and an important global public health challenge. Datamonitor estimates that there are currently 192m people with hypertension in the seven major markets, and this number is set to rise to 212m by 2015.
Reaching Endocrinologists Online: Strategies for Building Brand Equity
Reaching Endocrinologists Online: Strategies for Building Brand Equity
Endocrinologists play an important role in many of today's pressing healthcare issues, with diseases such as diabetes and obesity on the rise globally. Pharmaceutical companies can build brand equity by providing the eHealth tools that are most in demand from endocrinologists, as they rely increasingly on the Internet as a means to access information and improve patient care.
Pharmacovigilance: A New Era of Drug Safety
Pharmacovigilance: A New Era of Drug Safety
A series of high profile safety concerns, such as the withdrawal of Vioxx (rofecoxib) and the link between antidepressants and suicidal thoughts in children over the last two years has made drug safety a major issue for governments, regulatory authorities and the pharma industry.
India's Growth Prospects in Pharma: Evolution, Not Revolution
India's Growth Prospects in Pharma: Evolution, Not Revolution
The value of the Indian pharmaceutical industry grew 11% in 2004 from 2003; with the top 10 Indian pharmas accounting for 46% of the market, and R&D spend increasing by 36%. Compliance with international intellectual property protection and an increasing threat of foreign players moving into India are factors currently changing the dynamics of the market.
Medicare Part D - Its impact on US drug pricing issues and role as a driver towards European style pricing mechanisms
Medicare Part D - Its impact on US drug pricing issues and role as a driver towards European style pricing mechanisms
The imminent introduction of Medicare Part D will take place with the US drug market in a transitional period. Negative sentiment towards high prices in the US market has gained currency in recent years, while growth in generics continues to outstrip branded drug sales.
Pipeline Insight: Chronic and Acute Heart Failure - Diversity and Disappointment
Pipeline Insight: Chronic and Acute Heart Failure - Diversity and Disappointment
There is a clear need for new treatments for heart failure, as mortality and morbidity rates, although improving, remain high. Heart failure already represents the leading cause of hospitalization for patients over the age of 65 in Western markets and the aging population in these markets will surely lead to growth in the prevalence of the disease and an increase in healthcare expenditure.
Drug Delivery: Global Industry Guide
Drug Delivery: Global Industry Guide
Datamonitor's Drug Delivery: Global Industry Guide is an essential resource for top-level data and analysis covering the drug delivery industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies.
eHealth During the Clinical Trial Process - Trends in Study Participation and Clinical Trial Website Usage
eHealth During the Clinical Trial Process - Trends in Study Participation and Clinical Trial Website Usage
Inefficient patient recruitment slows the progress of many clinical trials. Online recruitment has the potential to alleviate some of the current delays. However, the success of this approach depends upon consumers' comfort levels with the clinical trial process.
The eHealth Market in Japan: Optimizing eHealth Tools for Reaching Consumers
The eHealth Market in Japan: Optimizing eHealth Tools for Reaching Consumers
The Internet is becoming a major source of healthcare and treatment information in Japan. In fact, Datamonitor research shows that surveyed consumers in Japan spend the most time online compared to surveyed consumers in the US and Europe.
Stakeholder Opinions: Sexually Transmitted Infections - The Silent Menace
Stakeholder Opinions: Sexually Transmitted Infections - The Silent Menace
The global incidence of STIs is estimated at several hundreds of millions cases per year, and due to the asymptomatic nature of most infections, underreporting is likely to mask the real incidence.
Commercial Insight: Asthma and COPD - Get SMART
Commercial Insight: Asthma and COPD - Get SMART
There is a positive outlook for the respiratory market over the next five years, which will experience a sustained period of growth driven by the expansion of sales in existing classes, the launch of major new products, and the results from several landmark studies.
Datamonitor's eHealth Consumer Insight Survey: 2005 Survey Results Overview
Datamonitor's eHealth Consumer Insight Survey: 2005 Survey Results Overview
As consumer use of the Internet for personal reasons increases, the influence of consumers on physicians and their prescribing decisions is also increasing. This PowerPoint presentation identifies current consumer usage and their preferences for online health information and services as well as emerging technologies that are impacting consumers' relationships with their physicians.
PROactive Results - The Diabetes Trial That Could Have Been
PROactive Results - The Diabetes Trial That Could Have Been
The socio-economic consequences of diabetes and its complications make it a major public health issue. Patients with diabetes have a 25% reduction in life expectancy compared with the general population, mainly due to cardiovascular deaths.
 Alzheimer's Disease - Beta treatments on the horizon
Alzheimer's Disease - Beta treatments on the horizon
Alzheimer's patients remain poorly treated and are growing in number. Currently, cholinesterase inhibitors and the more recent NMDA-receptor antagonists provide only moderate and temporary symptomatic benefit. By the end of the decade, however, drugs with the ability to slow the rate of disease progression are expected to be launched - most notably, the f


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright © 1997-2009 - BioPortfolio Limited.